Company News

World-class immunologist to advise Oxford Vacmedix on development of novel cancer vaccines. Oxford Vacmedix, a UK-based biopharma company focused on the development of cancer vaccines, announced today that Professor Sir Andrew McMichael will join the company’s Scientific Advisory Council. Sir Andrew is an immunologist, Emeritus Professor, former Professor of Molecular Medicine, and previously Director of the Weatherall Institute of Molecular Medicine at the University of Oxford. He was a pione...

Directors join Oxford Vacmedix from Myongji Hospital Group and Series A investors Cancer ROP in South Korea and Mr Jin from China. Oxford Vacmedix UK Limited (OVM), the UK-­‐based biopharma company focused on the development of cancer vaccines, confirmed today the appointment of new Directors to the Board. These new appointments follow the successful Series A investment and bring a wealth of experience and support for the company at a key stage in its development. The appointments are: Wang-�...

June 2018 – Oxford Vacmedix ROP technology presented at 2018 Myongji International Cancer Symposium View in PDF...

Oxford Vacmedix UK Limited (OVM) has completed its Series A financing round of $12.5m (£9m). Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company focused on the development of cancer vaccines, has completed its Series A financing round of $12.5m (£9m) with a consortium of South Korean and Chinese investors, including Cancer ROP, a leading South Korean healthcare institution listed in KOSDAQ. The financing round represents the first time that a UK cancer vaccines company has been fina...